Fulgent Genetics (NASDAQ:FLGT) Insider Hanlin Gao Sells 939 Shares

Fulgent Genetics, Inc. (NASDAQ:FLGT) insider Hanlin Gao sold 939 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $19.91, for a total transaction of $18,695.49. Following the completion of the transaction, the insider directly owned 987,790 shares of the company’s stock, valued at approximately $19,666,898.90. The trade was a 0.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Hanlin Gao also recently made the following trade(s):

• On Tuesday, June 2nd, Hanlin Gao sold 1,688 shares of Fulgent Genetics stock. The shares were sold at an average price of $17.89, for a total transaction of $30,198.32.

Fulgent Genetics Stock Performance

NASDAQ FLGT opened at $19.61 on Friday. The firm’s fifty day moving average price is $19.63 and its two-hundred day moving average price is $18.15. The stock has a market cap of $539.47 million, a PE ratio of -6.95 and a beta of 0.90. Fulgent Genetics, Inc. has a fifty-two week low of $13.46 and a fifty-two week high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. The firm had revenue of $85.39 million during the quarter, compared to the consensus estimate of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. As a group, sell-side analysts predict that Fulgent Genetics, Inc. will post -3.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on FLGT. Wall Street Zen upgraded Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Piper Sandler boosted their price target on Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings raised Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $27.50.

Hedge Funds Weigh In On Fulgent Genetics

A number of hedge funds have recently modified their holdings of the business. Allworth Financial LP bought a new stake in shares of Fulgent Genetics in the second quarter worth $25,000. Farther Finance Advisors LLC increased its holdings in Fulgent Genetics by 69.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after purchasing an additional 548 shares during the period. Kestra Advisory Services LLC acquired a new stake in Fulgent Genetics in the fourth quarter valued at $35,000. Legal & General Group Plc bought a new position in Fulgent Genetics during the 2nd quarter worth $38,000. Finally, Caitong International Asset Management Co. Ltd raised its position in Fulgent Genetics by 214.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock worth $48,000 after purchasing an additional 1,251 shares during the last quarter. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.